Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : EPY201
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : UCL Technology Fund
Deal Size : $10.0 million
Deal Type : Financing
EpilepsyGTx Raises $10 Million for CTA-Enabling Nonclinical Package for EPY201
Details : The funds raised will be used to complete the preclinical studies for EpilepsyGTx’ lead gene therapy program EPY201, for the treatment of focal refractory epilepsy.
Brand Name : EPY201
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 24, 2024
Lead Product(s) : EPY201
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : UCL Technology Fund
Deal Size : $10.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?